Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICAAC In Brief: SmithKline Beecham Famvir

Executive Summary

SmithKline Beecham Famvir: Famciclovir delays recurrent episodes of genital herpes in patients with frequently recurring disease who received 250 mg twice-daily doses of the antiviral for one year, according to results from a 455-patient trial presented at ICAAC. Median time to first clinically confirmed lesional episodes for patients treated with Famvir in the study was 11 months compared to 1.5 months for placebo-treated patients. Median time to first culture documented recurrence was more than one year for patients receiving Famvir and 2.7 months for patients on placebo...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028886

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel